Status:
UNKNOWN
Measuring Synovial Fluid Components
Lead Sponsor:
Dharma Bioscience
Conditions:
Knee Osteoarthritis
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Participants with grade 3 and 4 knee osteoarthritis will recieve aspiration of synoivial fluid, and then receive either dextrose, hemaotopoietic stem cell, or platelet rich plasma, or no injection. Th...
Detailed Description
80 participants with grade 3 and 4 symptomatic knee osteoarthritis, with a visable effusion, will receive aspiration of 3 ml of synovial fluid from the suprapatellar pouch, followed by either injectio...
Eligibility Criteria
Inclusion
- Inclusion Criteria:≥ 6 months of knee pain with walking
- ≥ 6/10 on a 0-10 point numerical rating scale
- High grade medial compartment cartilage loss ( Kellgren-Lawrence grade 3 or 4) on plain weight bearing X-ray
- Exposed subchondral bone at 110 degrees of flexion by ultrasound examination
- Easily visible suprapatellar pouch with quads conttraction.
- Exclusion Criteria
- Current intake of NSAIDs or steroids
- Current anticoagulation therapy
- Inflammatory or post-infectious knee arthritis
- Systemic inflammatory conditions
- Knee flexion less than 100 degrees
- Knee extension less than 165 degrees
- Valgus or varus more than 15 degrees
- Any knee injection in the precedign 3 months
- BMI more than 50 kg/ meter squared
- Gross synovial folds on ultrasound.
Exclusion
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05416255
Start Date
April 1 2022
End Date
December 31 2024
Last Update
April 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dharma Centro de Medicina Regenerativa
Rosario, Santa Fe Province, Argentina, 2000